NF-κB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53

Brain Research

Volumn 1145, Issue 1, 2007, Pages 190-203

  Liang, Zhong Qin ^a   Li, Yun Lin ^a   Zhao, Xi Lin ^a   Han, Rong ^a   Wang, Xiao Xia ^b   Wang, Yumei ^a   Chase, Thomas N ^b   Bennett, M Catherine ^c   Qin, Zheng Hong ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c Blanchette Rockefeller Neurosciences Institute   (United States)

Author keywords

6 Hydroxydopamine; c Myc; NF B; Oxidative stress; p53; Parkinson's disease

Indexed keywords

DNA FRAGMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; OXIDOPAMINE; PIFITHRIN ALPHA; PROTEIN P53; SN 50; TYROSINE 3 MONOOXYGENASE; ADRENERGIC RECEPTOR BLOCKING AGENT; BENZOTHIAZOLE DERIVATIVE; DOPAMINE; DRUG DERIVATIVE; NEUROTOXIN; PEPTIDE; PIFITHRIN; TOLUENE; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FOREBRAIN; GEL MOBILITY SHIFT ASSAY; GENE; GENE TARGETING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE DEGENERATION; NICK END LABELING; NONHUMAN; NUCLEOSOME; OXIDATIVE STRESS; P53 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; SILVER STAINING; SUBSTANTIA NIGRA; ACTIVE TRANSPORT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; NERVE CELL; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS; RODENTIA;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; APOPTOSIS; BENZOTHIAZOLES; DNA FRAGMENTATION; DOPAMINE; MALE; NERVE DEGENERATION; NEURONS; NEUROTOXINS; NF-KAPPA B; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53; TYROSINE 3-MONOOXYGENASE;

EID: 33947707798     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.01.130     Document Type: Article

References (58)

1. Alves da Costa C., Paitel E., Vincent B., and Checler F. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem. 277 (2002) 50980-50984
2. Alves da Costa C., Dunys J., Wilks S., Cappai R., and Checler F. 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J. Biol. Chem. 281 (2006) 9824-9831
3. Autere J.M., Hiltunen M.J., Mannermaa A.J., Jakala P.A., Hartikainen P.H., Majamaa K., Alafuzoff I., and Soininen H.S. Molecular genetic analysis of the alpha-synuclein and the parkin gene in Parkinson's disease in Finland. Eur. J. Neurol. 9 (2002) 479-483
4. Bennett M.C. The role of α-synuclein in neurodegenerative diseases. Pharmacol. Ther. 105 (2005) 311-331
5. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
6. Betarbet R., Sherer T.B., and Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's disease. Exp. Neurol. 191 Suppl. 1 (2005) 17-27
7. Biswas S., Ryu E., Park C., Malagelada C., and Greene L.A. Puma and p53 play required roles in death evoked in a cellular model of Parkinson disease. Neurochem. Res. 30 (2005) 839-845
8. Blum D., Wu Y., Nissou M.F., Arnaud S., Benabid A.L., and Verna J.M. P53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res. 751 (1997) 139-142
9. Burke R.E. Recent advances in research on Parkinson disease: synuclein and parkin. Neurologist 10 (2004) 75-81
10. Crumrine R.C., Thomas A.L., and Morgan P.F. Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J. Cereb. Blood Flow Metab. 14 (1994) 887-891
11. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
12. Dehmer T., Heneka M.T., Sastre M., and Dichgans J. Protection by pioglitazone in the model of Parkinson's disease correlates with IκBα induction and block of NF-κB and iNOS activation. J. Neurochem. 88 (2004) 494-501
13. Duan W., Zhu X., Ladenheim B., Yu Q.S., Guo Z., Oyler J., Cutler R.G., Cadet J.L., Greig N.H., and Mattson M.P. P53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 52 (2002) 597-606
14. Emerit J., Edeas M., and Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58 (2004) 39-46
15. Fornai F., Lenzi P., Gesi M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., and Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23 (2003) 8955-8966
16. France-Lanord V., Brugg B., Michel P.P., Agid Y., and Ruberg M. Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J. Neurochem. 69 (1997) 1612-1621
17. Gerlach M., Double K.L., Ben-Shachar D., Zecca L., Youdim M.B., and Riederer P. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox. Res. 5 (2003) 35-44
18. Glinka Y., Gassen Y., and Youdim M.B. Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural. Transm. Suppl. 50 (1997) 55-66
19. Huang Y.H., Wu J.Y., Zhang Y., and Wu M.X. Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-kappaB/rel complexes. Oncogene 21 (2002) 6819-6828
20. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., and Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 7531-7536
21. Jackson-Lewis V., and Smeyne R.J. MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Neurotox. Res. 7 (2005) 193-202
22. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36
23. Jones D.C., Prabhakaran K., Li L., Gunasekar P.G., Shou Y., Borowitz J.L., and Isom G.E. Cyanide enhancement of dopamine-induced apoptosis in mesencephalic cells involves mitochondrial dysfunction and oxidative stress. Neurotoxicology 24 (2003) 333-342
24. Junn E., and Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320 (2002) 146-150
25. Kaltschmidt B., Heinrich M., and Kaltschmidt C. Stimulus-dependent activation of NF-kappaB specifies apoptosis or neuroprotection in cerebellar granule cells. Neuromol. Med. 2 (2002) 299-309
26. Leker R.R., Aharonowiz M., Greig N.H., and Ovadia H. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp. Neurol. 187 (2004) 478-486
27. Levites Y., Youdim B.H., Maor G., and Mandel S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-κB) activation and cell death by tea extracts in neuronal cultures. Biochem. Parmacol. 63 (2002) 21-29
28. Liang Z.Q., Wang X.X., Wang Y., Chuang D.M., Difiglia M., Chase T.N., and Qin Z.H. Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity. Neurobiol. Dis. 20 (2005) 562-573
29. Lou Y., Hattori A., Munoz J., Qin Z.H., and Roth G.S. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-κB in rats. Mol. Pharmacol. 56 (1999) 254-264
30. Maeda M., Ampo K., Kiryu-Seo S., Konishi H., Ohba N., Kadono C., and Kiyama H. The p53-independent nuclear translocation of cyclin G1 in degenerating neurons by ischemic and traumatic insults. Exp. Neurol. 193 (2005) 350-360
31. Metodiewa D., and Koska C. Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. Neurotox. Res. 1 (2002) 197-233
32. Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58 (2002) 179-185
33. Nakai M., Qin Z.H., Chen J.F., Wang Y., and Chase T.N. Kainic acid-induced apoptosis is associated with NF-κB activation. J. Neurochem. 74 (2000) 647-658
34. 2 oxidation of dopamine. J. Med. Chem. 38 (1995) 917-922
35. Obata T., and Yamanaka Y. Parkinsonism induced by MPTP and free radical generation. Nippon Yakurigaku Zasshi 117 (2001) 105-110
36. Otsuka Y., Tanaka T., Uchida D., Noguchi Y., Saeki N., Saito Y., and Tatsuno I. Roles of cyclin-dependent kinase 4 and p53 in neuronal cell death induced by doxorubicin on cerebellar granule neurons in mouse. Neurosci. Lett. 365 (2004) 180-185
37. Panet H., Barzilai A., Daily D., Melamed E., and Offen D. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J. Neurochem. 77 (2001) 391-398
38. Papa S., and Skulachev V.P. Reactive oxygen species, mitochondria, apoptosis and aging. Mol. Cell. Biochem. 174 (1997) 305-319
39. +-induced dopaminergic neuronal cell death: its potential role as a survival determinant. Biochem. Biophys. Res. Commun. 322 (2004) 727-733
40. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1981), Academic Press
41. Pedrosa R., and Soares-da-Silva P. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by l-3,4-dihydroxyphenylalanine (l-DOPA) and dopamine. Br. J. Pharmacol. 137 (2002) 305-1313
42. Power J.H., Shannon J.M., Blumbergs P.C., and Gai W.P. Nonselenium glutathione peroxidase in human brain: elevated levels in Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 161 (2002) 885-894
43. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat. Disord. 11 Suppl. 1 (2005) S3-S7
44. Qin Z.H., Wang Y., and Chase T.N. Stimulation of N-methyl-d-aspartate receptors induces apoptosis in rat brain. Brain Res. 725 (1996) 166-176
45. Qin Z.H., Chen R.W., Wang Y., Nakai M., Chuang D.M., and Chase T.N. Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum. Mol. Pharmacol. 53 (1998) 33-42
46. Qin Z.H., Chen R.W., Wang Y., Nakai M., Chuang D.M., and Chase T.N. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J. Neurosci. 19 (1999) 4023-4033
47. Sakhi S., Bruce A., Sun N., Tocco G., Baudry M., and Schreiber S.S. Induction of tumor suppressor p53 and DNA fragmentation in organotypic hippocampal cultures following excitotoxin treatment. Exp. Neurol. 145 (1997) 81-88
48. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., and Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22 (2002) 7006-7015
49. Soos J., Engelhardt J.I., Siklos L., Havas L., and Majtenyi K. The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. NeuroReport 15 (2004) 715-1718
50. Tarabin V., and Schwaninger M. The role of NF-κB in 6-hydroxydopamine- and TNFα-induced apoptosis of PC12 cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 563-569
51. Tatton W.G., Chalmers-Redman R., Brown D., and Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degeneration. Ann. Neurol. 53 Suppl 3 (2003) S61-S72
52. Trimmer P.A., Smith T.S., Jung A.B., and Bennett Jr. J.P. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 5 (1996) 233-239
53. Vermes I., Steur E.N., Jirikowski G.F., and Haanen C. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov. Disord. 19 (2004) 1252-1264
54. Wood K.A., and Youle R.J. The role of free radicals and p53 in neuron apoptosis in vivo. J. Neurosci. 15 (1995) 5851-5857
55. Yoo M.S., Chun H.S., Son J.J., DeGiorgio L.A., Kim D.J., Peng C., and Son J.H. Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease. Brain Res. Mol. Brain Res. 110 (2003) 76-84
56. Youdim M.B., Grunblatt E., and Mandel S. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann. N. Y. Acad. Sci. 890 (1999) 7-25
57. Yu S., Ueda K., and Chan P. alpha-Synuclein and dopamine metabolism. Mol. Neurobiol. 31 (2005) 243-254
58. Zhang J., Fitsanakis V.A., Gu G., Jing D., Ao M., Amarnath V., and Montine T.J. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J. Neurochem. 84 (2003) 336-346